DK0910407T3 - Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons - Google Patents

Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons

Info

Publication number
DK0910407T3
DK0910407T3 DK96913660T DK96913660T DK0910407T3 DK 0910407 T3 DK0910407 T3 DK 0910407T3 DK 96913660 T DK96913660 T DK 96913660T DK 96913660 T DK96913660 T DK 96913660T DK 0910407 T3 DK0910407 T3 DK 0910407T3
Authority
DK
Denmark
Prior art keywords
immune response
antigen
composition
binding agent
multiepitope
Prior art date
Application number
DK96913660T
Other languages
Danish (da)
English (en)
Inventor
Birgit Schultes
Ragupathy Madiyalakan
Antoine A Noujaim
Richard P Baum
Original Assignee
Altarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Inc filed Critical Altarex Inc
Application granted granted Critical
Publication of DK0910407T3 publication Critical patent/DK0910407T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96913660T 1996-05-15 1996-05-15 Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons DK0910407T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1996/000461 WO1997042973A1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response

Publications (1)

Publication Number Publication Date
DK0910407T3 true DK0910407T3 (da) 2003-06-16

Family

ID=46171074

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96913660T DK0910407T3 (da) 1996-05-15 1996-05-15 Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons

Country Status (17)

Country Link
US (7) US6241985B1 (de)
EP (2) EP1297846A1 (de)
JP (1) JP3565351B2 (de)
KR (1) KR20020011137A (de)
AT (1) ATE233102T1 (de)
BR (1) BR9612619A (de)
CA (1) CA2253602A1 (de)
DE (1) DE69626423T2 (de)
DK (1) DK0910407T3 (de)
ES (1) ES2193240T3 (de)
HU (1) HUP9903770A3 (de)
IL (1) IL126803A (de)
NO (2) NO321511B1 (de)
NZ (3) NZ505174A (de)
PT (1) PT910407E (de)
SI (1) SI0910407T1 (de)
WO (1) WO1997042973A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
IL139832A0 (en) * 1998-06-15 2002-02-10 Altarex Inc Therapeutic compositions that produce an immune response by altering the antigen
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) * 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
GB2413960A (en) * 2001-03-21 2005-11-16 Altarex Inc Treating ovarian cancer
WO2002076384A2 (en) * 2001-03-21 2002-10-03 Altarex Corp. Therapeutic compositions that alter the immune response
WO2002084249A2 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
AU2002358246B2 (en) * 2001-10-26 2008-02-28 Oncoquest Pharmaceuticals Inc. Combination therapy for treating disease
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
US20050271649A1 (en) * 2002-10-17 2005-12-08 Schultes Birgit C Therapeutic adjuvant
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
JP5281399B2 (ja) * 2005-07-29 2013-09-04 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法
ZA200804078B (en) * 2005-10-13 2009-09-30 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
JP2007320969A (ja) * 2007-09-10 2007-12-13 Altarex Medical Corp 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US4997762A (en) 1984-01-31 1991-03-05 Akzo N.V. Tumor associated monocoloal antibodies derived from human B-cell line
US4740371A (en) * 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
US4940670A (en) 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
GB8610983D0 (en) 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US5194254A (en) 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US5084396A (en) * 1986-06-20 1992-01-28 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US4879225A (en) * 1986-06-20 1989-11-07 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US5009888A (en) 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
JPH02504517A (ja) 1987-08-19 1990-12-20 セントカー・インコーポレーテツド ヒト卵巣ガン腫に会合する抗原
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5140091A (en) * 1988-03-03 1992-08-18 Daicel Chemical Industries Ltd. Compositions of polyether compounds, epoxy compounds and processes for production thereof based on 4-vinylcyclohexene-1-oxide
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
CA1337403C (en) 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240833A (en) * 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
US5013547A (en) 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
JP3355351B2 (ja) * 1989-02-24 2002-12-09 ユーロジェン・ホールディング・ソシエテ・アノニム 遺伝的に工作されたイムノグロブリン
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5512283A (en) * 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
DK0629133T3 (da) 1992-01-03 2001-04-02 Rhomed Inc Farmaceutisk anvendelse af peptidmetalioner
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0699077B1 (de) 1993-05-07 2001-10-31 Akzo Nobel N.V. Hiv immunogene komplexe
CA2163868C (en) 1993-05-27 2008-01-08 Uwe Wagner Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
JPH10511846A (ja) * 1994-12-28 1998-11-17 ユニバーシティ オブ ケンタッキー ヒトガン胎児性抗原に関連する組換えモノクローナル抗イディオタイプ抗体３ｈ１配列
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
DE19531226C1 (de) * 1995-08-24 1997-04-03 Immuno Ag Pharmazeutische Zusammensetzungen, enthaltend ein neutralisiertes Virus, und Verwendung derselben
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
JPH1092532A (ja) * 1996-09-17 1998-04-10 Fujitsu Takamizawa Component Kk コネクタとｉｃカードコネクタ
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6052319A (en) * 1997-12-04 2000-04-18 Cypress Semiconductor Corp. Apparatus and method for controlling experimental inventory
KR100271642B1 (ko) * 1998-01-17 2000-11-15 김영환 다수의 문턱전압을 가지는 메모리 셀을 센싱 하는 회로 및 방법
JP3670839B2 (ja) * 1998-05-18 2005-07-13 オリンパス株式会社 共焦点顕微鏡

Also Published As

Publication number Publication date
NZ516264A (en) 2002-04-26
EP0910407B1 (de) 2003-02-26
ES2193240T3 (es) 2003-11-01
HUP9903770A3 (en) 2001-07-30
BR9612619A (pt) 1999-07-20
US20010036457A1 (en) 2001-11-01
US20080131443A1 (en) 2008-06-05
AU711270B2 (en) 1999-10-07
SI0910407T1 (en) 2003-10-31
IL126803A (en) 2003-11-23
NO321511B1 (no) 2006-05-15
AU5658096A (en) 1997-12-05
CA2253602A1 (en) 1997-11-20
NZ505174A (en) 2002-03-01
NO985304L (no) 1998-11-13
NO985304D0 (no) 1998-11-13
IL126803A0 (en) 1999-08-17
PT910407E (pt) 2003-07-31
US20080206318A1 (en) 2008-08-28
US20080311127A1 (en) 2008-12-18
DE69626423D1 (de) 2003-04-03
US6241985B1 (en) 2001-06-05
JP3565351B2 (ja) 2004-09-15
US6086873A (en) 2000-07-11
JPH11509558A (ja) 1999-08-24
EP1297846A1 (de) 2003-04-02
EP0910407A1 (de) 1999-04-28
WO1997042973A1 (en) 1997-11-20
NZ332588A (en) 2000-11-24
ATE233102T1 (de) 2003-03-15
DE69626423T2 (de) 2004-03-18
HUP9903770A2 (hu) 2000-03-28
US20070036798A1 (en) 2007-02-15
NO20061203L (no) 1998-11-13
KR20020011137A (ko) 2002-02-07

Similar Documents

Publication Publication Date Title
DK0910407T3 (da) Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons
NO20013906D0 (no) Fremgangsmater for behandling av tumorer og metastaser ved a bruke en kombinasjon av antiangiogeniske- og immunoterapier
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
NO862641D0 (no) Monoklonalt antistoff for et antigen tilknyttet human karsinoma tumor.
EP0939653A4 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
ATE267610T1 (de) Glykosylierte igg antikörper
HUP0200537A2 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
DK102589A (da) Antigen, der genkendes af mca 16-88
WO2003034977A3 (en) Combination therapy for treating disease
FI924576A0 (fi) Ctaa 28a32, antigen identiefierad av mca 28a32
WO1999043815A3 (en) Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
Gonzalez et al. EGF based cancer vaccine
WO1998023286A3 (en) Immunoconjugates comprising human monoclonal antibodies or fragments thereof for diagnostic and therapy
PL245361A1 (en) Method of obtaining antibodies specific for antigens isolated from human serum,in particular for the antigen hbs.
ATE17190T1 (de) Mittel zur tumorlokalisierung und therapie mit markierten antikoerpern und antikoerperfragmenten.